Vertex Pharmaceuticals

Vertex Pharmaceuticals

Vertex Pharmaceuticals was founded in 1989 by Joshua Boger, a former Merck senior chemist, to pursue structure-based, rational drug design. The company went public in 1991 and built its business by systematically targeting the underlying causes of diseases — most notably cystic fibrosis, where its suite of CFTR modulators transformed a fatal childhood disease into a chronic, manageable condition for the majority of patients. The firm's strategy centers on internal R&D programs aimed at specialty diseases with high unmet need and clear biological targets. Vertex's principal revenue comes from its cystic fibrosis therapies, including Trikafta/Kaftrio, which generated $8.9 billion in 2024 product revenue. Beyond CF, the company has advanced programs in sickle cell disease and beta thalassemia via Casgevy, a CRISPR-based gene therapy approved in late 2023. In January 2025, Vertex completed the acquisition of Alpine Immune Sciences for $4.9 billion, adding a clinical-stage autoimmune kidney disease program to its pipeline. Vertex operates from its headquarters in Boston's Seaport district, with additional research sites in San Diego, California, and Oxford, United Kingdom. The company employed 5,400 people as of year-end 2024. In April 2024, Vertex appointed Reshma Kewalramani, M.D., as CEO alongside her existing role as President, formalizing a leadership structure that has been in place since 2020. Vertex does not operate a venture capital arm, philanthropic foundation, or co-investment club. Vertex is structurally distinct in that it intentionally avoids the blockbuster primary care model in favor of what it calls a "serial innovation" strategy — solving one disease area completely before moving to the next. This creates a highly concentrated revenue profile that few public companies would tolerate. The firm's governance reinforces this: the board includes multiple academic physician-scientists, and R&D spending consistently exceeds 70% of total operating expenses — a ratio unheard of among comparable-cap pharma peers.